Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.

No abstract is available for this paper.

• Publication year

  1975

• Venue

  Gut

• Publication date

  1975-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/gut.16.11.876PMID 1104411PMCID PMC1413126
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic active liver disease reexamined: prognosis hopeful.

  1974influential reference
• Chronic active liver disease: classification and treatment.

  1973cited by this paper
• Controlled trial of prednisone and azathioprine in active chronic hepatitis.

  1973cited by this paper
• MALIGNANT TUMORS ARISING DE NOVO IN IMMUNOSUPPRESSED ORGAN TRANSPLANT RECIPIENTS

  1972cited by this paper
• Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution.

  1972cited by this paper
• Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis.

  1972influential reference
• Reduction of toxicity of corticosteroid therapy after renal transplantation.

  1972cited by this paper
• Malignant tumors arising de novo in immunosuppressed organ transplant recipients.

  1972cited by this paper
• Controlled prospective trial of corticosteroid therapy in active chronic hepatitis.

  1971influential reference
• Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy

  1971cited by this paper
• Prognosis of chronic persistent hepatitis.

  1970cited by this paper
• Long-term results of therapy in patients with chronic liver disease associated with hypergammaglobulinemia.

  1969influential reference
• Classification and treatment of chronic active liver disease.

  1968cited by this paper
• Chronic hepatitis: effect of prolonged suppressive treatment and comparison of azathioprine with prednisolone.

  1968cited by this paper
• Natural history of active chronic hepatitis. II. Pathology, pathogenesis and clinico-pathological correlation.

  1968cited by this paper
• Natural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality and survival.

  1968cited by this paper
• The treatment of active chronic hepatitis with 6-mercaptopurine and azathioprine.

  1967cited by this paper
• STUDIES ON AN INTERMITTENT CORTICOSTEROID DOSAGE REGIMEN.

  1963cited by this paper

• MMF Is an Effective and Safer Treatment Options for Treatment‐Naïve Patients With Autoimmune Hepatitis Compared to Azathioprine: A Systematic Review and Meta‐Analysis

  2025cites this paper
• Mycophenolate mofetil versus azathioprine as a first-line treatment for autoimmune hepatitis: a comparative systematic review and meta-analysis

  2025cites this paper
• Efficacy, Safety and Long-Term Clinical Outcomes of Low-Dose Versus High-Dose Prednisolone Induction in Autoimmune Hepatitis: A Propensity Score-Matched Analysis

  2025influential citation
• EASL Clinical Practice Guidelines on the management of autoimmune hepatitis.

  2025cites this paper
• Evolution of Therapy in Autoimmune Hepatitis.

  2025cites this paper
• Comparative Efficacy of Mycophenolate Mofetil vs. Azathioprine in Autoimmune Hepatitis: A Systematic Review and Meta-Analysis.

  2025cites this paper
• S3-Leitlinie „Seltene Lebererkrankungen (LeiSe LebEr) – Autoimmune Lebererkrankungen von der Pädiatrie bis zum Erwachsenenalter“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)

  2025cites this paper
• British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis

  2025cites this paper
• Diabetes Mellitus in Patients With Autoimmune Hepatitis: Frequency, Risk Factors and Effect on Outcome

  2025cites this paper
• Natural history and long–term management of autoimmune hepatitis

  2025cites this paper
• Temporal prescribing trends in AIH: exploring the influence of early thiopurine use on corticosteroid dependency and biochemical response

  2025cites this paper
• What is the optimal first-line treatment of autoimmune hepatitis? A systematic review with meta-analysis of randomised trials and comparative cohort studies

  2025cites this paper
• Development and validation of bleeding prediction model for percutaneous liver biopsy in children.

  2025cites this paper
• Hellenic Association for the Study of the Liver (HASL): revised clinical practice guidelines for autoimmune hepatitis

  2024cites this paper
• Autoimmune Hepatitis: Epidemiological and Therapeutic Aspects

  2024cites this paper
• Second- and third-line treatment agents in autoimmune hepatitis (AIH): Where do we stand?

  2024cites this paper
• Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis.

  2023cites this paper
• KASL clinical practice guidelines for management of autoimmune hepatitis 2022

  2023cites this paper
• 자가면역간염의 치료

  2023cites this paper
• Clinical trials reimagined.

  2023cites this paper
• RIP3 blockade prevents immune-mediated hepatitis through a myeloid-derived suppressor cell dependent mechanism

  2022cites this paper
• Is there any predictor for relapse after treatment withdrawal in autoimmune hepatitis patients in the real life?

  2022cites this paper
• Long-term results of mycophenolate mofetil vs. azathioprine use in individuals with autoimmune hepatitis

  2022cites this paper
• Mycophenolate mofetil as second line treatment in autoimmune hepatitis – A retrospective single center analysis

  2022cites this paper
• First Results From a Propensity Matching Trial of Mycophenolate Mofetil vs. Azathioprine in Treatment-Naive AIH Patients

  2022cites this paper
• Lactobacillus improves the effects of prednisone on autoimmune hepatitis via gut microbiota-mediated follicular helper T cells

  2022cites this paper
• Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group.

  2022cites this paper
• Extremely rare case of necrotizing gastritis in a patient with autoimmune hepatitis: A case report

  2021cites this paper
• Use of immunosuppression in non-transplant hepatology.

  2021cites this paper
• An update on the pharmacological management of autoimmune hepatitis

  2021cites this paper
• Patient Priorities in Autoimmune Hepatitis: The Need for Better Treatments, More Education and Challenging Stigma

  2021cites this paper
• The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis

  2021cites this paper
• Budesonide In The First Line Treatment Of Patients With Autoimmune Hepatitis

  2021cites this paper
• Ursodeoxycholic Acid Exhibits Anti-inflammatory Activity against Concanavalin A-induced Immune Hepatitis in Mice

  2021cites this paper
• The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage

  2020cites this paper
• Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis

  2020cites this paper
• Type 2 Autoimmune Hepatitis in a Male Patient with a Rare Complication of Vasculitis

  2020cites this paper
• Prognostic factors for remission, relapse, and treatment complications in type 1 autoimmune hepatitis

  2020cites this paper
• High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation

  2020cites this paper
• Autoimmune Hepatitis: a Review of Established and Evolving Treatments.

  2020cites this paper
• Autoimmune Hepatitis: Surviving Crises of Doubt and Elimination

  2020cites this paper
• Budesonide as a first line therapy in autoimmune hepatitis: A systematic review

  2020cites this paper
• Review article: experimental therapies in autoimmune hepatitis

  2020cites this paper
• Open challenges in the management of autoimmune hepatitis.

  2020cites this paper
• Approach to the patient with acute severe autoimmune hepatitis

  2020cites this paper
• Stopping immunosuppressive treatment in autoimmune hepatitis (AIH): Is it justified (and in whom and when)?

  2019cites this paper
• Autoimmune hepatitis: Epidemiology, prognosis and follow-up

  2019cites this paper
• The Evolving Landscape of Liver Cirrhosis Management

  2019cites this paper
• Adverse events related to low dose corticosteroids in autoimmune hepatitis

  2019cites this paper
• Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases

  2019cites this paper
• Clinical management of autoimmune hepatitis

  2019cites this paper
• Liver Cirrhosis with Autoimmune Liver Diseases: AIH and PBC

  2019cites this paper
• Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation?

  2019cites this paper
• Autoimmune Hepatitis

  2019cites this paper
• Comparative efficacy and tolerability of treatments for adult autoimmune hepatitis: A systematic review and network meta-analysis

  2018cites this paper
• Unmet needs and new models for future trials in autoimmune hepatitis.

  2018cites this paper
• Estrogen Deficiency Promotes Hepatic Steatosis via a Glucocorticoid Receptor-Dependent Mechanism in Mice

  2018cites this paper
• The Saudi Association for the Study of Liver Diseases and Transplantation clinical practice guidelines for management of autoimmune hepatitis

  2018cites this paper
• Autoimmunhepatitis – Standard- und Zweitlinientherapie

  2018cites this paper
• The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility

  2018cites this paper
• The Effectiveness and Tolerability of Budesonide in Treatment of Autoimmune Hepatitis: A Systematic Review

  2018cites this paper
• Protective effects of Punica granatum (pomegranate) peel extract on concanavalin A-induced autoimmune hepatitis in mice.

  2018cites this paper
• Autoimmunhepatitis

  2018cites this paper
• Efficacy and Limitations of Budesonide as a Second‐Line Treatment for Patients With Autoimmune Hepatitis

  2017cites this paper
• AUTOIMMUNE HEPATITIS AND PREGNANCY

  2017cites this paper
• Autoimmune Hepatitis in the Asia-Pacific Area

  2017cites this paper
• S2k Leitlinie Autoimmune Lebererkrankungen

  2017cites this paper
• Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments

  2017cites this paper
• [Practice guideline autoimmune liver diseases - AWMF-Reg. No. 021-27].

  2017cites this paper
• Clinical usefulness of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis

  2017cites this paper
• New predictive factors of poor response to therapy in autoimmune hepatitis: role of mean platelet volume

  2017cites this paper
• Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review

  2017cites this paper
• The use of immunosuppression in autoimmune hepatitis: A current literature review

  2017cites this paper
• Autoimmune Liver Diseases: Autoimmune Hepatitis

  2017cites this paper
• Salvage Therapies for Autoimmune Hepatitis: A Critical Review

  2017cites this paper
• Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions

  2016cites this paper
• The clinical phenotypes of autoimmune hepatitis: A comprehensive review.

  2016cites this paper
• Auto immune hepatitis.

  2016cites this paper
• Treatment Withdrawal in Autoimmune Hepatitis

  2015cites this paper
• Standard Treatment in Adults: Which Steroid? Or without Steroids?

  2015cites this paper
• 99. Autoimmune Hepatitis

  2015cites this paper
• Diagnosis and management of autoimmune hepatitis.

  2015cites this paper
• Chapter 1 An update of Auto Immune Hepatitis : epidemiology , clinical aspects and treatment Submitted

  2015cites this paper
• EASL Clinical Practice Guidelines: Autoimmune hepatitis.

  2015cites this paper
• Autoimmune hepatitis--Update 2015.

  2015cites this paper
• Prediction of short‐ and long‐term outcome in patients with autoimmune hepatitis

  2015cites this paper
• Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use

  2015cites this paper
• Systemic Glucocorticoid Therapy: a Review of its Metabolic and Cardiovascular Adverse Events

  2014cites this paper
• Current and prospective pharmacotherapy for autoimmune hepatitis

  2014influential citation
• Autoimmune hepatitis in southern Israel: A 15‐year multicenter study

  2013cites this paper
• Acute and Acute Severe (Fulminant) Autoimmune Hepatitis

  2013cites this paper
• Autoimmune Hepatitis: Clinical Review with Insights into the Purinergic Mechanism of Disease

  2013cites this paper
• Review article: the management of autoimmune hepatitis beyond consensus guidelines

  2013cites this paper
• Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission.

  2013cites this paper
• Current trends in the diagnosis and treatment of autoimmune hepatitis in Japan

  2012cites this paper
• Drug Therapy in the Management of Type 1 Autoimmune Hepatitis

  2012influential citation
• Der Einfluss der Leberzirrhose bei Diagnose auf den Verlauf der Autoimmunen Hepatitis

  2012cites this paper
• Drug choices in autoimmune hepatitis: Part B – nonsteroids

  2012cites this paper
• Management of patients with difficult autoimmune hepatitis

  2012cites this paper
• Autoimmunerkrankungen der Leber

  2012cites this paper